Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Louisiana: - Abbeville General Hospital — Abbeville, Louisiana
- LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Medical Center of Baton Rouge — Baton Rouge, Louisiana
- Ochsner High Grove — Baton Rouge, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Louisiana: - GSK Investigational Site — Baton Rouge, Louisiana
Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Louisiana: - University Medical Center New Orleans — New Orleans, Louisiana
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Louisiana: - Local Institution - 2116 — New Orleans, Louisiana
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Louisiana: - Our Lady of the Lake — Baton Rouge, Louisiana
Phase 2 Recruiting Industry
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…
Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Louisiana: - Central Recruiting Site — Lake Charles, Louisiana
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. Th…
Sponsor: Delcath Systems Inc.
NCT ID: NCT06607458
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana
Phase 1 Recruiting Industry
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in Louisiana: - Mary Bird Perkins Cancer Ctr — Baton Rouge, Louisiana
Phase 1 Recruiting Industry
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the…
Sponsor: Astellas Pharma Inc
NCT ID: NCT07094204
Sites in Louisiana: - Ochsner Health — Jefferson, Louisiana
NA Recruiting Academic/Other
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Sponsor: NRG Oncology
NCT ID: NCT05080673
Sites in Louisiana: - Louisiana State University Health Science Center — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
- LSU Health Sciences Center at Shreveport — Shreveport, Louisiana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Louisiana: - Ochsner LSU Health Monroe Medical Center — Monroe, Louisiana
- LSU Health Sciences Center at Shreveport — Shreveport, Louisiana
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Louisiana: - Ochsner Medical Center Jefferson — New Orleans, Louisiana
Recruiting Industry
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individ…
Sponsor: Guardant Health, Inc.
NCT ID: NCT06880055
Sites in Louisiana: - Northlake Gastroenterology Associates — Covington, Louisiana
- Northlake Gastroenterology Associates — Hammond, Louisiana
Phase 4 Recruiting Industry
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory me…
Sponsor: Takeda
NCT ID: NCT06562543
Sites in Louisiana: - Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology — Baton Rouge, Louisiana
- Willis Knighton Cancer Center — Shreveport, Louisiana
Recruiting Industry
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advance…
Sponsor: Universal Diagnostics
NCT ID: NCT04792684
Sites in Louisiana: - Ochsner Clinic — New Orleans, Louisiana